Contact us
Call us
Chat with us
PDA Technical Report No. 27 provides a comprehensive framework for ensuring container/closure integrity, emphasizing a lifecycle approach to prevent sterilization failures. The report guides manufacturers in selecting appropriate test methods, such as vacuum decay, to evaluate the barrier qualities of sterile packaging. For more information, visit Parenteral Drug Association Technical Report No. 27: Pharmaceutical Package Integrity
Understanding PDA Technical Report No. 27: Pharmaceutical Package Integrity
PDA Technical Report No. 27 (TR 27), titled "Pharmaceutical Package Integrity," is a foundational consensus document published by the Parenteral Drug Association (PDA) in 1998. It provides comprehensive guidance on evaluating the barrier qualities and integrity of pharmaceutical packaging throughout a product's lifecycle. Overview and Purpose
This report was developed by the PDA Task Force on Container/Closure Integrity to address the evolving complexities of pharmaceutical packaging. While it covers various nonporous barrier systems, its primary focus is on packaging for sterile products. TR 27 superseded the earlier "PDA Technical Information Bulletin No. 4" and introduced updated terminology, such as using "product package" instead of "container/closure system" to encompass all barrier systems. Key Content and Framework
The report is structured to assist users in developing robust integrity assessment strategies. Major sections include:
Integrity Assurance: Guidance on maintaining barrier quality from product development through its entire life cycle.
Design and Process Development: Detailed considerations for package design, process development, and durability assessments. pda technical report 27 pdf
Leak Rate Specifications: Establishing specifications for what constitutes a "leak" for specific product types.
Test Method Selection: Factors to consider when choosing between various physical and microbial test methods.
Microbial Package Integrity: Methods for establishing a correlation between physical leak tests and microbial ingress.
Decision Tree: A structured tool to help manufacturers determine the most appropriate integrity testing strategy. Transition to TR 86
It is important to note that as of 2021, the Parenteral Drug Association has largely transitioned from TR 27 to PDA Technical Report No. 86 (TR 86), "Industry Customization of Container Closure Integrity Testing". TR 86 serves as the modern successor, reflecting updated regulatory expectations and advancements in Container Closure Integrity Testing (CCIT) technologies. How to Access PDA Technical Reports
PDA reports are generally available through the PDA Bookstore: PDA Technical Report No
Digital Format: Reports are typically available as single-user PDFs for purchase.
Membership Benefits: Qualifying PDA members can often view active publications for free on the PDA Technical Report Portal or download newly released reports within a specific window. Technical Report No. 27: Pharmaceutical Package Integrity
PDA Technical Report No. 27, "Pharmaceutical Package Integrity," provides a comprehensive framework for validating the barrier properties of sterile drug packaging throughout its lifecycle. It emphasizes a science-based, risk-based approach, advocating for deterministic, quantitative leak detection methods over traditional, subjective tests. More information on the report is available through the Parenteral Drug Association (PDA) bookstore.
PDA Technical Report No. 27, "Pharmaceutical Package Integrity," provides comprehensive guidance on Container Closure Integrity Testing (CCIT) to ensure the barrier quality of pharmaceutical packaging, particularly for sterile products. It outlines strategies for establishing integrity standards and selecting appropriate test methods, such as helium mass spectrometry and microbial challenge, throughout the product lifecycle. The full report is available for purchase at the PDA Bookstore. Technical Report No. 27: Pharmaceutical Package Integrity
If you download TR 27 today, you must read it with one major caveat: It was supplemented (and largely superseded) by PDA TR 86.
Why TR 27 is still worth the read: Even though TR 86 is the current operational bible, TR 27 contains the scientific arguments that justify why we do what we do today. It provides excellent educational background on fluid dynamics and leak physics that later reports assume you already know. dye ingress for large-volume bags).
TR 27 defines integrity not as a binary "pass/fail" based on visual inspection, but as the ability of a container to prevent the loss of sterility or product quality. It introduces the concept that integrity is a probability, not an absolute.
Let’s debunk a few myths that persist online, even in 2025.
Myth #1: “TR 27 says dye ingress is dead.” Reality: TR 27 states dye ingress is a “coarse leak test” suitable for quality control sampling, but it is not sensitive enough for small molecule or biologic products that require <1 µm integrity.
Myth #2: “If I have TR 84, I can ignore TR 27.” Reality: No. If your product was validated between 1998 and 2020, your submission likely references TR 27. You must keep a copy for historical reference during audits.
Myth #3: “The PDF is free because PDA is a non-profit.” Reality: PDA is a non-profit, but it receives no government funding. Publication sales fund research and standards development. Respect the copyright.
Searching for a “PDA technical report 27 pdf” is more than a hunt for a file; it is a search for industry consensus on how to keep sterile drugs safe. For over two decades, this document has prevented countless contamination recalls and patient injuries.
While PDA TR 84 now leads the way, TR 27 remains a vital part of pharmaceutical history and regulatory compliance. To protect your career and your patients, always obtain the official PDF from PDA, use its principles to build robust CCIT programs, and stay current with new deterministic technologies.
Use the TR 27 risk matrix to determine if your product requires 100% online testing (e.g., HVLD for ampoules) versus batch sampling (e.g., dye ingress for large-volume bags).
